TLR4 and hydrops fetalis: Moreover, TLR4 inhibitor was shown to reduce Ly6Chigh and CD11b+ monocytes in spleen and peripheral blood (Wu et al., 2017), which is considered the most attractive therapeutic strategy for anti-inflammation in HF patients.